NMPA grants priority review for HUTCHMED’s NSCLC combo
The combination is aimed at treating patients with locally advanced or metastatic non-small cell lung cancer. Credit: JOURNEY STUDIO7/Shutterstock. China National Medical Products Administration (NMPA)